CAC2 Childhood Cancer Community News Digest (June 27-July 3)
Assorted News from Last Week:
Childhood cancer survivors of certain racial and ethnic groups were prone to more hospitalizations for various conditions years down the road.
Survivorship Matters Blog: Recapturing the Dream
NCI’s new Molecular Characterization Initiative (MCI) is expanding comprehensive molecular characterization of tumors to children, adolescents, and young adults (AYAs) with newly diagnosed soft tissue sarcomas receiving care at hospitals affiliated with the Children’s Oncology Group.
Intratumoral infusion of an oncolytic virus offered safe and feasible results, along with encouraging efficacy, in pediatric patients with diffuse intrinsic pontine glioma (DIPG).
Some children with a type of brain cancer called low-grade glioma may have a new standard treatment, according to the results of a new clinical trial. In the study, the combination of dabrafenib (Taflinar) and trametinib (Mekinist) was safer and better than standard chemotherapy at shrinking tumors and keeping them at bay.
Upcoming Webinars, Online Opportunities, and Meetings:
Join advocates from around the country for the 2022 Rally for Medical Research! The Hill Day will take place on Wednesday, September 14, with advocates meeting their congressional representatives and staff. The evening before, on September 13, there will be a reception to celebrate medical research with all partners and participants.
Children’s Cancer Cause is hosting a virtual externally-led Patient-Focused Drug Development (PFDD) meeting on Reducing Cardiac Late Effects in Pediatric Cancer Survivors, on September 15, 2022. The conference is an opportunity for survivors and caregivers to educate representatives of the FDA, academic researchers, and pharmaceutical companies about their personal experiences managing the impact of cardiac late effects on daily living and long-term health. Registration link.
Save the Date: Key experts from across the pediatric cancer ecosystem will address the promise and challenges of artificial intelligence implementation in drug development, diagnosis and clinical trial design in the CureSearch Summit Prelude: The Challenges and Promise of Artificial Intelligence in Drug Development on September 15, 2022 3:30PM –5PM (EST).
Recordings of Recent Past Events:
Children’s Cancer Cause has established an annual award, the Survivorship Champion’s Prize, to be presented to a group, program or institution making significant advances in programs and services to provide life-long health maintenance for survivors of pediatric cancers. These awards recognize the importance of the unique challenges associated with the post-treatment services for survivors, especially as they transition to non-oncology adolescent and/or adult health care services. This year, there are awards in two categories (click here for more information and to apply):
- Champion’s Prize Award: $10,000
- Recognition Awards for 1) Program Impact; 2) Collaboration; and 3) Scalability: $5,000 each
During June, on Childhood Cancer International social media wants to share stories, testimonials and activities regarding childhood cancer survivorship. If you have content that would like to share with us please send it to .
- Blog Posts (65)
- Guest Blogs (18)
- Member Blogs (24)
- Survivorship Matters Blog (9)
- CAC2 News (20)
- Collaborative Achievements (13)
- Community News (159)
- News Digest (119)
- Research Explained (10)
- Webinars (61)
- CAC2 Childhood Cancer Community News Digest (March 13-19)
- CAC2 Childhood Cancer Community News Digest (March 6-12)
- Make Your Voice Heard Alliance for Childhood Cancer Action Days 2023
- CAC2 Childhood Cancer Community News Digest (February 27-March 5)
- Guest Blog–Molecular Characterization Initiative (MCI) Continues to Enroll